Table 4 Incidence of grade 3 or 4 edema... | American Society of Hematology

Table 4

Incidence of grade 3 or 4 edema and fluid retention in imatinib studies

	N	Median follow-up, mo	Dose, mg	No. patients (%)M
	N	Median follow-up, mo	Dose, mg	Superficial edema	Fluid retention (other)
CML²²	532	18	400	5 (1)	3 (0.6)
CMLBP²³	260	4	400/600	9 (5)	8 (6)
CMLAP²⁴	235	10	400/600	6 (4)	7 (3)
GM²⁵	33	15	500/1000	2 (6)	1 (3)
ALL relapse²⁶	56	NA	400/600	1 (2)	1 (2)
GIST³	147	10	400/600	—	2 (1.4)
Melanoma²⁷	26	NA	800	—	2 (8)
ALL⁶	80	13	600	—	2 (3)
ALL⁵	20	20	400	—	1 (5)

	N	Median follow-up, mo	Dose, mg	No. patients (%)M
	N	Median follow-up, mo	Dose, mg	Superficial edema	Fluid retention (other)
CML²²	532	18	400	5 (1)	3 (0.6)
CMLBP²³	260	4	400/600	9 (5)	8 (6)
CMLAP²⁴	235	10	400/600	6 (4)	7 (3)
GM²⁵	33	15	500/1000	2 (6)	1 (3)
ALL relapse²⁶	56	NA	400/600	1 (2)	1 (2)
GIST³	147	10	400/600	—	2 (1.4)
Melanoma²⁷	26	NA	800	—	2 (8)
ALL⁶	80	13	600	—	2 (3)
ALL⁵	20	20	400	—	1 (5)

GM indicates glioblastoma multiforme; ALL, acute lymphoblastic leukemia; GIST, gastrointestinal stromal tumor; —, not applicable.

Fluid retention events include pleural effusion, ascites, pulmonary edema, pericardial effusion, anasarca, aggravated edema, and fluid retention not otherwise specified

View Large